• COVID-19
  • For Special Populations

I have an oncology patient, age 27, who was up to date on COVID-19 vaccination but is now in need of hematopoietic cell transplant (HCT). Will she require revaccination after HCT?

Yes. See revaccination considerations after HCT and for those on B-cell depleting therapies, at www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#considerations-COVID-19-revaccination. This is the most current statement from CDC on COVID-19 vaccination after HCT:

Recipients of HCT or CAR-T-cell therapy who received 1 or more doses of COVID-19 vaccine prior to or during treatment should be revaccinated. Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy and should follow the currently recommended schedule for immunocompromised people who are unvaccinated.

A patient’s clinical team is best positioned to determine the degree of immune compromise, need for revaccination, and appropriate timing of revaccination.

Last reviewed: August 31, 2024

This page was updated on .